Case Studies
Please browse these pages to find out more about successful spin-out companies and licensing deals negotiated by Warwick Ventures on behalf of the University of Warwick.
4D Medicine Ltd formed to take new biomaterials to market
4D Medicine has developed a patented range of novel polymeric 3-D printing resin-inks that can be printed into solid 3D scaffold implants to help patients recover from major medical procedures.
Rapid diagnostic test for COVID-19
University of Warwick researchers are developing a new test for Coronavirus which potentially offers significant benefits because it delivers a very rapid result and requires no specialist lab equipment or training to complete. The result is that people could determine very quickly whether they have a current infection and take appropriate action.
Care Companion demonstrates vital role of online resources in carers’ wellbeing during lockdown
Care Companion, the online tool for carers has been updated specifically to provide relevant information and to support wellbeing during coronavirus lockdown.
Sarissa Biomedical develops rapid test for stroke
Sarissa Biomedical has developed the world’s first blood test for stroke. It is a simple finger-prick blood test delivering greater diagnostic accuracy within 3 minutes, helping rapid intervention to prevent less severe disabilities and shorter hospital stays.
Medherant partners with Cycle Pharmaceuticals for pipeline expansion
Cycle will utilise Medherant’s proprietary TEPI Patch® transdermal delivery technology to develop formulations that will address patients’ unmet needs such as dysphagia and dyskinesia, further expanding its pipeline.
ECG based low-level glucose detection
A new technology for detecting low glucose levels via ECG using a non-invasive wearable sensor, which with the latest Artificial Intelligence can detect hypoglycaemic events from raw ECG signals has been made by researchers from the University of Warwick.
Cytecom - portable bacteria detection device offers faster diagnostics
A discovery by researchers at the University of Warwick School of Life Sciences offers a new technology for detecting bacteria in minutes instead of waiting for lab-test results which can take days. Delays in detection can cause significant damage; infections can become life threatening very quickly if not identified and treated with appropriate antibiotics. For example, 8% of people with the severe blood infection sepsis will die for every hour of delay in proper treatment.
Medherant – innovative transdermal drug delivery moves to the next stage
Medherant has completed two Phase I clinical studies with its novel transdermal drug delivery technology, the TEPI Patch®. There is considerable interest in the transdermal delivery of drugs to overcome some of the disadvantages of oral administration, such as spikes in drug levels that can lead to side effects, and poor compliance. Patches are also a more convenient way to deliver drugs through the skin than gels and creams and provide better dose control.
Q-Eye Sensors – high-speed, ultra-sensitive Terahertz sensing platform for security screening and medical imaging
Terahertz (THz) frequency radiation is a solution for the growing $500bn market for faster, more sensitive and more accurate medical imaging, security screening and product safety inspection. It is intrinsically safe, non-ionising and non-destructive. It can be used for high speed imaging and to probe spectroscopic signatures of explosives and other materials, even when hidden or in degraded visual environments. It can be used for stand-off, covert detection in personnel and crowd screening. Q-Eye Sensors is developing a THz sensing and imaging platform that enables inspection and screening devices that are orders of magnitude faster than those currently available, with a sensitivity that can detect a single photon and even see round corners.
Pioneering hip replacement tool launched in US
Warwick Ventures works closely with academics to ensure that the University’s innovative technologies are protected and made available for companies to license.
Our approach has resulted in some significant successes, including a deal with the international orthopaedic company Voyant Health (now part of Brainlab) to license a measuring device developed in the University’s medical school for use in hip replacement